Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC

The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.

Keeping Track Feature image

The US Food and Drug Administration continues to defy the constraints of the pandemic by not only meeting but exceeding user fee goal dates for a steady, high volume of approval actions.

The speed of FDA review can be seen particularly for the novel agents, a closely-watched regulatory metric. Three of the four recent new molecular entity approvals came at least one...

More from US FDA Performance Tracker

More from Regulatory Trackers